Novel Sarcoidosis Drug Fails to Improve Steroid Dose Reduction
Summary
(MedPage Today) -- The novel immunomodulatory agent efzofitimod failed to reduce steroid use in pulmonary sarcoidosis, a phase III trial showed. Monthly infusions of the fusion protein targeting the neuropilin 2 receptor had no impact on placebo...
Description from Medpagetoday.
Who is covering this
-
Novel Sarcoidosis Drug Fails to Improve Steroid Dose Reduction
(MedPage Today) -- The novel immunomodulatory agent efzofitimod failed to reduce steroid use in pulmonary sarcoidosis, a phase III trial showed. Monthly infusions of the fusion protein targeting the neuropilin 2 receptor had no impact on placebo...
